I

InventisBio Co Ltd
SSE:688382

Watchlist Manager
InventisBio Co Ltd
SSE:688382
Watchlist
Price: 29.87 CNY 1.19% Market Closed
Market Cap: 17.3B CNY

InventisBio Co Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

InventisBio Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
I
InventisBio Co Ltd
SSE:688382
Revenue
ÂĄ168.8m
CAGR 3-Years
N/A
CAGR 5-Years
25%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
ÂĄ27.2B
CAGR 3-Years
53%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Revenue
ÂĄ11.4B
CAGR 3-Years
36%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Revenue
ÂĄ2.1B
CAGR 3-Years
111%
CAGR 5-Years
97%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
ÂĄ2.2B
CAGR 3-Years
-27%
CAGR 5-Years
14%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Revenue
ÂĄ1.9B
CAGR 3-Years
291%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

InventisBio Co Ltd
Glance View

Market Cap
17.3B CNY
Industry
Biotechnology

Amidst the dynamic landscape of biopharmaceutical innovation, InventisBio Co. Ltd. stands as a testament to cutting-edge drug discovery and development. Founded in 2013, this Shanghai-based company carves its niche by focusing on novel small-molecule therapeutics. The company's prowess lies in its ability to combine deep scientific expertise with robust research methodologies, positioning itself as a key player in addressing unmet medical needs, particularly in oncology and metabolic diseases. By leveraging its proprietary technology platforms, InventisBio designs and synthesizes innovative compounds, pushing them through rigorous preclinical and clinical evaluations. This strategy showcases the company’s commitment to bringing first-in-class and best-in-class drugs to the market, underscoring its drive to reshape therapeutic paradigms. InventisBio's revenue model pivots around strategic partnerships, collaborations, and licensing agreements, which enable the monetization of its scientific breakthroughs. The firm collaborates with major pharmaceutical companies, academia, and research institutions, sharing risks and benefits in advancing its pipeline. Additionally, by out-licensing its drug candidates at various development stages, InventisBio capitalizes on milestone payments and royalties. This blend not only fuels its research endeavors but also ensures a steady influx of capital to sustain its operations. Such a framework exemplifies how InventisBio has adeptly harmonized scientific ingenuity with business acumen, positioning itself as a formidable entity in the global pharmaceutical arena.

Intrinsic Value
9.33 CNY
Overvaluation 69%
Intrinsic Value
Price
I

See Also

What is InventisBio Co Ltd's Revenue?
Revenue
168.8m CNY

Based on the financial report for Dec 31, 2024, InventisBio Co Ltd's Revenue amounts to 168.8m CNY.

What is InventisBio Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
25%

Over the last year, the Revenue growth was -9%.

Back to Top